Once again, a big hedge fund is trying to convince the Allergan (AGN) board to split the roles of chairman and chief executive into separate positions and address “chronic underperformance.”

In a brief but pointed letter, Appaloosa Management criticized the board for ignoring the same request last spring and contended its refusal makes the company an “outlier.” In arguing its case, the fund cited ISS Analytics data showing the percentage of S&P 500 companies with dual chairs and chief executives was 45.6 percent in 2018, down from 48.7 percent the year before and the lowest percentage in at least a decade.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy